Levomilnacipran

DRUG5 trials

Sponsors

University of Minnesota, Forest Laboratories, University of California, Los Angeles, Duke University, University of Ottawa

Conditions

Major Depressive DisorderNone (i.e. Healthy Volunteers)Tobacco Use Disorder

Phase 3

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

CompletedNCT02431806

Forest LaboratoriesMajor Depressive Disorder

Start: 2015-06-23End: 2019-08-19Updated: 2020-09-07

Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD

CompletedNCT02720198

Duke UniversityMajor Depressive Disorder

Start: 2017-01-23End: 2018-06-12Updated: 2019-08-14

Phase 4

Trial of Levomilnacipran in Geriatric Depression

CompletedNCT02466958

University of California, Los AngelesMajor Depressive Disorder

Start: 2016-06-30End: 2018-12-09Updated: 2019-08-14

Levomilnacipran in Healthy Males

University of OttawaNone (i.e. Healthy Volunteers)

Start: 2018-03-02End: 2022-05-01Updated: 2021-10-06

Unknown Phase

Novel Medication as a Potential Smoking Cessation Aid

CompletedNCT02265367

University of MinnesotaTobacco Use Disorder

Start: 2015-01-31End: 2017-05-31Updated: 2022-04-22

Related Papers

Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range

The Journal of Clinical Psychiatry2025-08-25

Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7–17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies

Journal of Child and Adolescent Psychopharmacology2024-05-035 citations

The intestinal microbiota as a predictor for antidepressant treatment outcome in geriatric depression: a prospective pilot study.

2021-03-2432 citations